RxDoctor Payments Data

Donald Messersmith, MD

Cardiovascular Disease · Merritt Island, FLNPI 1538235338

Payments from drug & device makers

$1,365in general payments, 2019–2025

Across 87 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$238
  • Pfizer$184
  • Novartis$184
  • Amgen$148
  • E.r. Squibb & Sons, L.L.C.$147
  • AstraZeneca$76
  • plus $388 from 11 others

What the payments were for

  • Food & beverage$1,35199%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,365 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$311,261
Medicare patients
986
Services billed
3,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban635$727,422
EntrestoSacubitril/Valsartan227$273,784
XareltoRivaroxaban212$245,843
Repatha SureclickEvolocumab173$171,272
FarxigaDapagliflozin Propanediol123$108,422
Praluent PenAlirocumab32$40,940
JardianceEmpagliflozin29$40,254
BrilintaTicagrelor14$14,415
Metoprolol Succinate786$11,509
Rosuvastatin Calcium780$10,635
Ezetimibe458$9,379
Diltiazem 24hr Er (Cd)Diltiazem Hcl156$5,430
Carvedilol502$4,988
Amlodipine Besylate730$4,703
Atorvastatin Calcium502$4,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$184$727,422635 claims
NovartisEntresto$184$273,784227 claims
Johnson & JohnsonXarelto$238$245,843212 claims
AstraZenecaFarxiga, Brilinta$76$122,837137 claims
Boehringer IngelheimJardiance$47$40,25429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Merritt Island

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →